What BlueRidge Life Sciences does

BlueRidge Life Sciences is a life sciences consulting platform formed in March 2025 through the unification of four established firms—Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies—under a single brand backed by Renovus Capital Partners. The company delivers integrated scientific, regulatory, clinical, and engineering services to pharmaceutical, biotechnology, medical device, food, chemical, consumer product, and government clients, spanning the full therapeutic product lifecycle from pre-clinical through commercialization. Its service portfolio includes nonclinical toxicology, clinical development and regulatory strategy, cold chain engineering, medical device and combination product consulting, epidemiology and biostatistics, health economics and outcomes research (HEOR), human factors engineering, and environmental risk assessment.

The technical platform combines proprietary methodologies such as Cold Chain Engineering™ practices, physiologically based pharmacokinetic (PBPK) modeling, quantitative structure-activity relationship (QSAR) tools, and New Approach Methodologies (NAMs) that reduce reliance on animal testing. BlueRidge operates through multiple sub-brands (Clintrex Research, EpidStrategies, HEORStrategies, ToxStrategies, Modality Solutions, Suttons Creek, BlueRidge Pharmaceutical Commercialization) that maintain domain identity while enabling cross-selling and integrated delivery. The platform expanded in January 2026 with the acquisition of Design Science, adding human factors engineering, usability testing capabilities, and operational footprint in Philadelphia, Chicago, and Munich.

Revenue is generated through fee-for-service consulting engagements, typically structured as multi-year or project-based contracts with enterprise clients. The company employs a sales-led, enterprise field sales go-to-market model, engaging clients through direct outreach, industry events, and referrals. With 51-200 professionals post-acquisition, BlueRidge serves a roster of named enterprise clients including Acadia Pharmaceuticals, Annexon, Cerevance, Novelis, Ovid Therapeutics, PhotoPharmics, and Serina Therapeutics, with several relationships exceeding 5-10 years in tenure.

Name

BlueRidge Life Sciences

Legal name

BlueRidge Life Sciences

Website

https://blueridgelifesciences.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

51–100 employees

Short description

BlueRidge Life Sciences is a PE-backed life sciences consulting platform integrating toxicology, regulatory, clinical, cold chain engineering, HEOR, and human factors services for pharmaceutical, biotech, medical device, and chemical clients from pre-clinical through commercialization.

Ownership category

akta.pro rank

Product category

Life Sciences Consulting Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

akta.pro secondary industries

CMC Regulatory Affairs (Modules 2/3, Variations, Post-Approval CMC) (HLAGAKAB), Manufacturing Quality Assurance & GMP Compliance (batch release, deviation/CAPA, tech transfer QA) (HLAGAKAJ), Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent) (HLAGAKAO), Life Sciences & Biotech (R&D/Clinical) Staffing (BPACADAL), CMC, Process Development & Tech Transfer Staffing FSP (HLAGAOAK)

Keywords

• Life sciences consulting
• Regulatory strategy services
• Nonclinical toxicology consulting
• Clinical development advisory
• Health economics outcomes research

Headquarters

HQ city

Westlake Village

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Life Sciences Consulting Services: BlueRidge Life Sciences operates as a professional consulting firm providing integrated scientific, regulatory, clinical, and engineering services to life sciences companies. Revenue is generated through fee-for-service consulting engagements across toxicology, regulatory science, epidemiology, clinical development, HEOR, cold chain engineering, and related disciplines. Engagements span the full product lifecycle from pre-clinical through commercialization, with clients typically entering multi-year or project-based consulting contracts.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

BlueRidge Life Sciences is an integrated life sciences consulting firm providing scientific, regulatory, clinical, engineering, and commercialization services to pharmaceutical, biotechnology, medical device, food, consumer products, chemical, energy, and government clients. Service offerings span Device and Combination Products, Epidemiology and Biostatistics, Exposure Sciences, Food and Consumer Product Safety, Human Factors, Life Sciences Supply Chain Engineering, New Approach Methodologies, Nonclinical Safety, Occupational and Environmental Health, Pharmaceutical Commercialization, and Therapeutic Development. Engagements are delivered as fee-for-service consulting projects from pre-clinical through commercialization.

Product overview

BlueRidge Life Sciences is a comprehensive life sciences consulting platform formed by unifying four companies—Suttons Creek, Modality Solutions, Clintrex Research, and ToxStrategies—now operating as a portfolio company of Renovus Capital Partners. The company provides an integrated suite of services organized around core consulting practices: Clintrex Research (CNS clinical development and regulatory strategy), EpidStrategies (epidemiology and biostatistics), HEORStrategies/BlueRidge Pharmaceutical Commercialization (health economics and market access), ToxStrategies (nonclinical toxicology), Modality Solutions (cold chain engineering), and Suttons Creek (medical device and combination product development). The platform spans consulting services across drug lifecycle, device/combination products, epidemiology, exposure sciences, food safety, human factors, nonclinical safety, and therapeutic development.

Differentiator

Problem solved

Functional benefit

Brands

• Clintrex Research: Strategic guidance on CNS therapies from pre-clinical trial design through regulatory submissions, and investor strategies.
• EpidStrategies
• HEORStrategies
• BlueRidge Pharmaceutical Commercialization
• Modality Solutions
• Suttons Creek Inc.
• ToxStrategies
• Design Science

Products and services

• Therapeutic Development Services Cross-division integrated expertise supporting pharmaceuticals, biologics, and medical device development from discovery through commercialization across therapeutic areas including CNS, rare diseases, oncology, and autoimmune conditions.
• Device & Combination Products Services Consulting services for developers of innovative drug/biologic + device products, including drug delivery systems, diagnostics, and device-based therapies, supporting from planning through commercialization.
• Epidemiology & Biostatistics Services Innovative and robust solutions for conducting, evaluating, and interpreting epidemiological studies, including evidence generation, real-world data and evidence (RWD/RWE), and regulatory submissions.
• Exposure Sciences Services Assessment of exposure to chemicals and radionuclides in air, water, soil, sediments, biota, food and consumer products, with customized industrial hygiene and occupational safety services.
• Food & Consumer Product Safety Services Safety and risk assessments for foods, dietary supplements, cosmetics, personal care products, and raw ingredients, including regulatory compliance support under FSMA and MOCRA.
• Human Factors Services Human factors engineering and usability testing services including use-related risk analysis and regulatory submission support for medical devices and combination products, delivered via usability labs in Philadelphia, Chicago, and Munich.
• Life Sciences Supply Chain Engineering Services Cold chain engineering and transport validation solutions ensuring integrity of temperature-sensitive therapeutics and novel fragile drug products, including thermal modeling, chamber testing, and transport validation simulations.
• New Approach Methodologies (NAMs) Services Application of New Approach Methodologies (NAMs) to reduce reliance on animal models in research and human health risk assessment, including in vitro assays, in silico tools, and systematic literature reviews for evidence-based toxicology.
• Nonclinical Safety Services Risk assessment and toxicology services including systematic literature reviews, evidence-based toxicology, and NAMs implementation for environmental and occupational exposures.
• Occupational and Environmental Health Services Occupational and environmental health consulting including industrial hygiene, exposure monitoring, radiologic risk assessment, environmental compliance, and decommissioning support.
• Pharmaceutical Commercialization Services Pharmaceutical commercialization services defining the value of therapies for payers, patients and providers through health economics and outcomes research (HEOR), pricing strategies, and reimbursement planning.

Quantifiable outcome

• Supported FDA approval of Daybue (trofinetide) for Rett syndrome through cold chain consulting
• +2 more outcomes

Named customers10 records

Segments8 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Design SciencecoreOthers · 22 January 2026BlueRidge Life Sciences acquired Design Science, a Philadelphia-based human factors and usability engineering consultancy serving medical device, pharmaceutical, and biotechnology companies. Design Science was founded in 1991 and operates usability labs in Philadelphia, Chicago, and Munich. The acquisition adds human factors engineering, usability testing, and use-related risk analysis capabilities to BlueRidge's suite of consulting services. Design Science continues under its existing brand with CEO Katie Hansbro leading the team of 50+ professionals.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BlueRidge Life Sciences